NCT00411749View on ClinicalTrials.gov

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

December 11, 2006

Primary Completion Date

September 18, 2009

Study Completion Date

September 18, 2009

Conditions
HPV Infections
Interventions
BIOLOGICAL

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)

V501; Gardasil, 0.5 ml injection in 3 dosing regimen

BIOLOGICAL

Comparator: Placebo (unspecified)

Placebo 0.5 ml injection in 3 dosing regimen

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00411749 - V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) | Biotech Hunter | Biotech Hunter